The $540m venture financing of Noom was the medical devices industry’s top venture financing deal as total deals worth $3bn were announced globally in May 2021, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 32.5% over the previous month of $2.28bn and a rise of 92.4% when compared with the last 12-month average, which stood at $1.57bn.
Comparing venture financing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $1.92bn. At the country level, the US topped the list in terms of deal value at $1.92bn.
In terms of volumes, North America emerged as the top region for medical devices industry venture financing deals globally, followed by Asia-Pacific and then Europe.
The top country in terms of venture financing deals activity in May 2021 was the US with 59 deals, followed by the China with 18 and the UK with ten.
In 2021, as of May, medical devices venture financing deals worth $9.97bn were announced globally, marking an increase of 43.03% year on year.
medical devices industry venture financing deals in May 2021: Top deals
The top five medical devices industry venture financing deals accounted for 37.9% of the overall value during May 2021.
The combined value of the top five medical devices venture financing deals stood at $1.15bn, against the overall value of $3bn recorded for the month.
The top five medical devices industry venture financing deals of May 2021 tracked by GlobalData were:
1) Novo Holdings, Oak HC/FT Partners, RRE Ventures, Samsung Ventures Investment, Sequoia Capital Operations, Silver Lake Management and Temasek Holdings (Private)’s $540m venture financing of Noom
2) The $200m venture financing of Esco Micro by China Investment, EDBI, Novo Holdings and Vivo Capital
3) 8VC , Adage Capital Partners, Biospring Partners, Bristol-Myers Squibb, D1 Capital Partners, General Atlantic, General Catalyst Partners, Kaiser Permanente Ventures, KdT Ventures, LabCorp Venture Fund, Merck Global Health Innovation Fund, Polaris Partners, Refactor Capital and Tiger Global Management’ $165m venture financing of PathAI
4) The $130m venture financing of Huma Therapeutics by HAT SGR, Hitachi Ventures, Leaps by Bayer, Samsung NEXT Fund, Sony Innovation Fund and Unilever Ventures
5) AME Cloud Ventures, Ardea Partners, Aspect Ventures, AXA Venture Partners, Canvas Ventures, Centene, General Atlantic, NGP Capital and Workday Ventures’ venture financing of Vida Health for $110m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.